Pay in 4 interest-free payments of $5.44 Learn more
Ships within 48 hours · Estimated delivery Sep 24 - Sep 29
Body composition Unlike some peptides, GHK-CU protocols typically use fixed doses rather than weight-based calculations
Another 2021 study found that 2.4 milligrams (mg) of semaglutide once per week plus lifestyle interventions (diet and physical activity) led to sustained weight loss in patients who were overweight or obese
Patients typically use it as part of a multi-peptide protocol, with mucosal improvements building over 612 weeks
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
US$ 26.23
US$ 23.06
US$ 24.41
US$ 28.48
US$ 28.36
US$ 20.15
US$ 22.18
